Video

Educated Patient® Multiple Myeloma Summit: March 13, 2021

Author(s):

CURE Media Group

View the full CURE Educated Patient Multiple Myeloma Summit on demand.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Related Content
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 1st 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.
cancer horizons image for podcast
August 1st 2025

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
August 1st 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
Cancer Horizons podcast logo
August 1st 2025

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 1st 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Image of kidney.
August 1st 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.